Goodman Corey S's Form 4 filing
Elevation Oncology, Inc. · filed Jul 1, 2021
- Accession no.
- 0001567619-21-012858
- Filed
- Jul 1, 2021, 5:27 PM ET
- Trade date
- Jun 29, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market purchases total $10.0M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Goodman Corey SCIK 0001278411 | 10% Owner |
| Adelman Robert JCIK 0001329161 | 10% Owner |
| Royston AaronCIK 0001727703 | 10% Owner |
| venBio Global Strategic Fund III, L.P.CIK 0001739920 | 10% Owner |
| Venbio Global Strategic GP III, L.P.CIK 0001869303 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 29, 2021 | Common Stock | CConversionAcquired | +1,983,167 | –F1 | – | 1,983,167 | Direct | |
| Jun 29, 2021 | Common Stock | PPurchaseAcquired | +625,000 | $16.00 | +$10,000,000 | 2,608,167 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 29, 2021 | Common Stock | CConversionDisposed | −1,983,167 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each share of Series B Preferred Stock automatically converted into approximately 0.236654 shares of the Issuer's common stock immediately prior to the completion of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date.
Referenced by the price of 1 transaction in Table I.